{"doi":"10.5301/ejo.5000478","title":"Retinal and Choroidal Thickness Changes after Single Anti-VEGF Injection in Neovascular Age-related Macular Degeneration: Ranibizumab vs Bevacizumab","abstract":"<jats:sec>\n                    <jats:title>Purpose</jats:title>\n                    <jats:p>To evaluate and compare the effects of single intravitreal injection of ranibizumab and bevacizumab on central retinal and choroidal thickness in patients with neovascular age-related macular degeneration (AMD).</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods</jats:title>\n                    <jats:p>Forty eyes of 40 patients with neovascular AMD that underwent intravitreal injection of vascular endothelial growth factor inhibitors (anti-VEGFs) were included. Patients were randomized into 2 groups: 20 eyes received ranibizumab and 20 eyes received bevacizumab injection. Central retinal and choroidal thicknesses of all eyes at baseline and 1 month postinjection scans were measured with Fourier-domain optical coherence tomography (OCT). Student t test and Mann-Whitney U test were used to compare the data.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Results</jats:title>\n                    <jats:p>The mean central retinal thickness (CRT) showed significant decrease after single injection of ranibizumab (from 345.0 μm to 253.5 μm, p&lt;0.01) and bevacizumab (from 329.5 μm to 251.0 μm, p&lt;0.01) at the first month, respectively. There was no significant difference regarding the CRT change between groups (p = 0.39). The mean choroidal thickness decreased from 158.6 μm (115-317) to 155.5 μm (111-322) in the ranibizumab group and from 211.5 μm (143-284) to 201.5 μm (93-338) in bevacizumab group. The decrease was not significant between groups (p = 0.35).</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions</jats:title>\n                    <jats:p>Intravitreal injection of both ranibizumab and bevacizumab provided a significant decrease in CRT; however, the agents caused no significant change in choroidal thickness. Additionally, no difference between ranibizumab versus bevacizumab was observed related to macular edema inhibition.</jats:p>\n                  </jats:sec>","journal":"European Journal of Ophthalmology","year":2014,"id":685562,"datarank":0.5050943744979712,"base_score":3.367295829986474,"endowment":3.367295829986474,"self_citation_contribution":0.5050943744979712,"citation_network_contribution":0.0,"self_endowment_contribution":0.5050943744979712,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":28,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1791116,"name":"Cem Kucukerdonmez","orcid":null,"position":1,"is_corresponding":false},{"id":1791117,"name":"Ali Kal","orcid":null,"position":2,"is_corresponding":false},{"id":1791118,"name":"Eylem Yaman Pinarci","orcid":null,"position":3,"is_corresponding":false},{"id":1791119,"name":"Handan Canan","orcid":null,"position":4,"is_corresponding":false},{"id":1791120,"name":"Gürsel Yilmaz","orcid":null,"position":5,"is_corresponding":false},{"id":1791115,"name":"Selcuk Sizmaz","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Retinal and Choroidal Thickness Changes after Single Anti-VEGF Injection in Neovascular Age-related Macular Degeneration: Ranibizumab vs Bevacizumab","abstract":"<jats:sec>\n                    <jats:title>Purpose</jats:title>\n                    <jats:p>To evaluate and compare the effects of single intravitreal injection of ranibizumab and bevacizumab on central retinal and choroidal thickness in patients with neovascular age-related macular degeneration (AMD).</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods</jats:title>\n                    <jats:p>Forty eyes of 40 patients with neovascular AMD that underwent intravitreal injection of vascular endothelial growth factor inhibitors (anti-VEGFs) were included. Patients were randomized into 2 groups: 20 eyes received ranibizumab and 20 eyes received bevacizumab injection. Central retinal and choroidal thicknesses of all eyes at baseline and 1 month postinjection scans were measured with Fourier-domain optical coherence tomography (OCT). Student t test and Mann-Whitney U test were used to compare the data.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Results</jats:title>\n                    <jats:p>The mean central retinal thickness (CRT) showed significant decrease after single injection of ranibizumab (from 345.0 μm to 253.5 μm, p&lt;0.01) and bevacizumab (from 329.5 μm to 251.0 μm, p&lt;0.01) at the first month, respectively. There was no significant difference regarding the CRT change between groups (p = 0.39). The mean choroidal thickness decreased from 158.6 μm (115-317) to 155.5 μm (111-322) in the ranibizumab group and from 211.5 μm (143-284) to 201.5 μm (93-338) in bevacizumab group. The decrease was not significant between groups (p = 0.35).</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions</jats:title>\n                    <jats:p>Intravitreal injection of both ranibizumab and bevacizumab provided a significant decrease in CRT; however, the agents caused no significant change in choroidal thickness. Additionally, no difference between ranibizumab versus bevacizumab was observed related to macular edema inhibition.</jats:p>\n                  </jats:sec>","is_dataset_classified":null,"base_score":3.367295829986474,"endowment":3.367295829986474,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"24803153","pmcid":null,"openalex_id":"https://openalex.org/W2014975030","authors":[],"funders":[],"total_grants":0,"fwci":3.4058,"citation_percentile":0.91200645,"influential_citations":0,"citation_trend":[{"year":2013,"count":1},{"year":2015,"count":6},{"year":2016,"count":5},{"year":2017,"count":1},{"year":2018,"count":1},{"year":2019,"count":4},{"year":2020,"count":1},{"year":2021,"count":1},{"year":2022,"count":1},{"year":2023,"count":1},{"year":2024,"count":4},{"year":2025,"count":2}],"oa_status":"closed","license":"https://journals.sagepub.com/page/policies/text-and-data-mining-license","oa_locations":[{"url":"https://journals.sagepub.com/doi/pdf/10.5301/ejo.5000478","host_type":"publisher"},{"url":"https://journals.sagepub.com/doi/full-xml/10.5301/ejo.5000478","host_type":"publisher"},{"url":"https://doi.org/10.5301/ejo.5000478","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/24803153","host_type":"repository"}],"fields_of_study":["Retinal Diseases and Treatments","Ocular Diseases and Behçet’s Syndrome","Ophthalmology and Visual Impairment Studies","Aged","Aged, 80 and over","Angiogenesis Inhibitors","Antibodies, Monoclonal, Humanized","Bevacizumab","Choroid","Female","Fourier Analysis","Humans","Intravitreal Injections","Male","Middle Aged","Ranibizumab","Retina","Retrospective Studies","Tomography, Optical Coherence","Vascular Endothelial Growth Factor A","Visual Acuity","Wet Macular Degeneration"],"mesh_terms":["Bevacizumab","Ranibizumab","Aged","Aged, 80 and over","Choroid","Female","Fourier Analysis","Humans","Male","Middle Aged","Retina","Retrospective Studies","Visual Acuity","Angiogenesis Inhibitors","Tomography, Optical Coherence","Vascular Endothelial Growth Factor A","Wet Macular Degeneration","Intravitreal Injections","Antibodies, Monoclonal, Humanized"],"keywords":["Ranibizumab","Medicine","Bevacizumab","Macular degeneration","Ophthalmology","Retinal","Choroidal neovascularization","Surgery","Chemotherapy"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-18T16:59:29.776211Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}